Arena/Eisai anti-obesity drug wins US FDA nod; CVOT postapproval, no REMS
This article was originally published in Scrip
Executive Summary
Obese and overweight patients will have a new drug to combat those conditions with the US FDA giving its final blessing on 27 June to Arena Pharmaceuticals’ and Eisai's lorcaserin, which will be sold in the US under the brand name Belviq as an adjunct to a reduced-calorie diet and exercise for chronic weight management.